StockData
C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc. (CCCC) stock

CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/302% below fair value
$2.53−0.12 (-4.53%)

Close on Nov 17, 2026Market cap $311.25MP/E –Yield –

C4 Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

C4 Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $35.04M, up 2.3% year over year. For fiscal 2025 it was $35.95M, up 1.0% from the year before. The highest annual figure on record is $45.79M in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$35.95M+1.0%
FY2024Dec 31, 2024$35.58M+71.4%
FY2023Dec 31, 2023$20.76M-33.3%
FY2022Dec 31, 2022$31.10M-32.1%
FY2021Dec 31, 2021$45.79M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$6.64M+2.8%
Q1 FY2026Mar 31, 2026$6.15M-15.0%
Q4 FY2025Dec 31, 2025$11.02M+112.8%
Q3 FY2025Sep 30, 2025$11.23M-26.9%
Q2 FY2025Jun 30, 2025$6.46M-46.2%
Q1 FY2025Mar 31, 2025$7.24M+138.2%
Q4 FY2024Dec 31, 2024$5.18M+58.8%
Q3 FY2024Sep 30, 2024$15.36M+38.7%
Q2 FY2024Jun 30, 2024$12.01M+350.7%
Q1 FY2024Mar 31, 2024$3.04M-19.2%
Q4 FY2023Dec 31, 2023$3.26M+14.3%
Q3 FY2023Sep 30, 2023$11.07M+63.9%
Q2 FY2023Jun 30, 2023$2.66M-80.7%
Q1 FY2023Mar 31, 2023$3.76M-50.9%
Q4 FY2022Dec 31, 2022$2.85M-85.8%
Q3 FY2022Sep 30, 2022$6.75M-20.5%
Q2 FY2022Jun 30, 2022$13.83M+41.4%
Q1 FY2022Mar 31, 2022$7.65M–
Q4 FY2021Dec 31, 2021$20.08M–
Q3 FY2021Sep 30, 2021$8.50M–
Q2 FY2021Jun 30, 2021$9.78M–

More C4 Therapeutics figures

See a number that looks wrong?